Advaxis‘ cancer vaccine, axalimogene filolisbac, significantly increased cervical cancer patients’ 12-month survival rate, according to a clinical trial. Patients with persistent or recurrent metastatic carcinoma of the cervix (PRmCC) who took the ... Read more